Mission Complete: Mevion Medical Systems to showcase the MEVION S250-FIT Proton Therapy System^TM, a revolutionary patient-centric proton therapy solution designed to FIT in a conventional LINAC vault.

Mevion Medical Systems, the leading provider of compact single-room proton therapy systems, will showcase products and solutions to re-imagine proton therapy by breaking down access barriers at the upcoming American Society of Radiation Oncology 65^th Annual Meeting (ASTRO 2023).

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230928893588/en/

Mevion Booth #2435 at ASTRO 2023 (Photo: Business Wire)

Key highlights from Mevion at the ASTRO 2023 Annual Meeting will include:

1. Breaking Site and Cost Barriers: Mission Complete - FIT Proton Therapy in your LINAC Vault
   
   
   
   The MEVION S250-FIT Proton Therapy System™ is the world’s first proton therapy system designed to FIT in a conventional LINAC vault.
   
   
   
   The FIT proton therapy system is a collaborative effort with Leo Cancer Care, a medical device company based in Middleton, Wisconsin, and the leading provider of upright radiation therapy solutions. The collaboration aims to accelerate proton therapy developments for clinical use, making it more accessible to patients who need it most. Healthcare communities will have more opportunities to upgrade existing radiation oncology service lines or build new cancer centers with the latest FIT proton therapy technology.
   
   
   
   Mevion and Leo Cancer Care have worked in tandem to successfully install a MEVION S250-FIT system within a conventional LINAC-sized vault at Mevion’s headquarters in Littleton, MA.
   
   
   
   
2. Breaking Technological and Clinical Barriers: Re-imagine Innovations
   
   
   
   Mevion re-imagines the clinical and research possibilities across the Mevion portfolio of products and solutions, bringing scalable technologies for MEVION S250i and MEVION S250-FIT platforms. Innovations that will be highlighted at ASTRO 2023 include HYPERSCAN pencil beam scanning IMPT with pMLC, ARC therapy IMPT, and FLASH proton therapy for research applications. These innovations are designed to improve treatment efficiency and quality, enhance patient experience, and ultimately impact outcomes.
   
   
   
   
3. Breaking Service Line Barriers: Path-to-Success Solutions
   
   
   
   Mevion is committed to removing the entry barriers to proton therapy and will showcase new solutions and services for healthcare communities that could not consider proton therapy due to staggering financial costs and complex siting and utility requirements.

“We are thrilled to announce that ‘Mission Impossible’ is now a ‘Mission Complete’ at this year’s meeting,” said Tina Yu, Ph.D., CEO and President of Mevion Medical Systems. “The Mevion team with our valued partner, Leo Cancer Care, has installed the first proton therapy system in a single conventional LINAC-sized space at Mevion headquarters. We are breaking down barriers this year and are excited to bring new proton solutions and services to improve access to all healthcare systems. Today, our collaborative innovations and plethora of solutions are transforming the industry, and Mevion is proud to lead the way.”

Rock Mackie, Ph.D., Board Chairman and Co-Founder of Leo Cancer Care, stated, “Like Mevion, our approach to cancer care focuses on the patient's experience. By teaming up with Mevion, we achieved what many thought impossible. We have scaled proton therapy down in size and reduced costs and barriers of entry, making proton therapy more accessible to patients.”

Mevion proton therapy experts will be available at Mevion Booth #2435 to explore ideas that expand access to proton therapy treatment technology in your community during the ASTRO 65^th Annual Meeting on October 1-3, 2023 in San Diego, CA.

*The MEVION S250-FIT Proton Therapy System, FLASH therapy, online adaptive therapy, and ARC therapy are not yet available for clinical use.

About Mevion Medical Systems

Mevion Medical Systems is the leading provider of compact proton therapy systems for cancer care. Dedicated to advancing the design and accessibility of proton therapy worldwide, Mevion pioneered the single-room platform and continues to further the science and application of proton therapy. Since 2013, Mevion compact proton therapy single-room systems have been used by leading cancer centers for treating patients. Mevion's series of products, including the flagship MEVION S250i and MEVION S250-FIT* with HYPERSCAN pencil beam scanning, represent the world's most compact proton therapy systems that eliminate the obstacles of size, complexity, and cost. Mevion is headquartered in Littleton, Massachusetts with a presence in Europe and Asia. For more information, please visit www.mevion.com.

About MEVION S250-FIT Proton Therapy System™

Enabled by the world’s smallest self-shielded proton accelerator, the MEVION S250-FIT Proton Therapy System™ is the first and only proton therapy system designed to FIT in a single existing conventional LINAC vault. The FIT system features the industry-leading HYPERSCAN® Pencil Beam Scanning for Intensity Modulated Proton Therapy (IMPT) with pMLC, and an upright patient positioner with a large bore diagnostic CT from Leo Cancer Care for IGRT and adaptive therapy. FIT is also designed to support fast access to emerging technologies like ARC therapy, adaptive planning, dual-energy CT (DECT), FLASH therapy, and more.

Connect with us on:

Twitter: @MevionMedical

LinkedIn: Mevion Medical Systems

Facebook: MevionMedical

Instagram: mevionmedicalsystems

View source version on businesswire.com: https://www.businesswire.com/news/home/20230928893588/en/